Navellier & Associates Inc Supernus Pharmaceuticals, Inc. Transaction History

Navellier & Associates Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 15, 2019	SELL	$30.84 - $49.51 $503,031 - $807,557	-16,311 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $17,507 - $23,185	410 Added 2.58%	16,311 $821,000
Q2 2018 Aug 06, 2018	BUY	$44.1 - $59.85 $701,234 - $951,674	15,901 New	15,901 $952,000

260

57.3M

84.1K

61.2K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.39B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.